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To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus
on speciﬁc issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11–12
May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in
each of four areas: pathology and molecular biomarkers, ﬁrst-line/second and further lines of treatment in advanced
disease, early-stage disease and locally advanced disease. For each question, recommendations were made including ref-
erence to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.
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methods
A detailed literature review was done by the writing group for
this manuscript and was extended after sending out the prelimin-
ary paper to all other Panel Members (see Appendix). All avail-
able meta-analysis, randomized phase III trials and phase II trials
considered by the panel as of key importance were put forward
for the scoring of the guidelines. The scores for level of evidence
and grade of recommendation were proposed and fully consented
within the writing committee that met at the Consensus
Conference in Lugano. In an initial summary discussion meeting
at the Consensus Conference, these scores were already presented
to the full Consensus Panel and evaluated and amended when-
ever necessary. During the ﬁnal writing process, these scores were
further consented within the writing group together with the full
consensus panel. Final given levels of evidence and grades of rec-
ommendation in this manuscript were consented without signiﬁ-
cant divergence between the different panel members if not
otherwise openly speciﬁed in the text (Table 1). Statements
without grading were considered standard clinical practice by the
experts. The methods both for the conference and the writing
process for this topic were as those for the other three manu-
scripts produced from this conference [2–4]. To minimise
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potential bias from the Consensus Panel and writing group, the
full multidisciplinary manuscript input came from medical
oncologists, radiation oncologists, thoracic surgeons, pulmonolo-
gists and also from pathologists and molecular pathologists.
This manuscript covers locally advanced disease deﬁned as
stage III disease determined at initial staging, as well as stage III
disease found as pathological stage III following upfront surgical
resection treatment. Table 2 shows the different patient subsets
of stage III non-small-cell lung cancer (NSCLC). The Robinson
Classiﬁcation that includes subsets of patients that are found
only to be pathologically within stage III disease (IIIA1 and
IIIA2) is mentioned here and later in the text for historical
reasons (see also Table 2). Some centres still classify patients
within stage IIIA(N2) based on these criteria although, general-
ly, this classiﬁcation has lost some of its importance in guiding
treatment algorithms for individual treatment decisions.
introduction
heterogeneity in disease
Locally advanced NSCLC in this manuscript is deﬁned as stage
III NSCLC patients according to the most recent (7th) edition of
the International Association for the Study of Lung Cancer
(IASLC)/ Union for International Cancer Control (UICC) TNM
staging classiﬁcation. Stage III NSCLC represents a heteroge-
neous group of patients even in the most recent version of the
IASLC/UICC TNM staging system (7th edition) [5]. The treat-
ment of such patients may be a challenge because of their local
presentation, especially in the case of an advanced primary
tumour (T4 situation) with local inﬁltration of vital mediastinal
organs or involvement of locoregional mediastinal lymph nodes
(N2 or N3 nodes) and the risk of metastatic recurrence (see
Table 2) [5]. Consequently, the IIIA subset is still to be differen-
tiated from the IIIB subset of NSCLC. Deﬁnitive cure rates as
well as long-term prognosis differ signiﬁcantly between these
two sub-stages (see Table 2) [5].
Furthermore, most randomised studies were carried out in
the pre-positron emission tomography (PET) scan era. The high
rate of undiagnosed distant metastases in these patients has
most probably diluted any real effect of local control on the
overall outcome. Thus, the current stage III NSCLC population
has changed as well as the related treatment [6, 7]. These
changes also contribute to the difﬁculty of interpreting results.
Improved outcomes of stage III patients in current studies com-
pared with previous trials may result from stage migration,
because of the increased use of PET and magnetic resonance
imaging (MRI) of the brain. There have been improvements in
surgery (lung-sparing techniques, minimally invasive surgery,
pre- and post-operative care), radiotherapy (e.g. image guidance,
adaptive and respiratory movement techniques) and adjuvant or
neoadjuvant chemotherapy has become a standard of care in
operable stage III patients [8, 9]. Adjuvant chemotherapy is
Table 1. Levels of evidence and grades of recommendation
(adapted from the Infectious Diseases Society of America-United
States Public Health Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of
good methodological quality (low potential for bias) or meta-
analyses of well-conducted randomised trials without heterogeneity
II Small randomised trials or large randomised trials with a suspicion
of bias (lower methodological quality) or meta-analyses of such
trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the
risk or the disadvantages (adverse events, costs,…), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
aBy permission of the Infectious Diseases Society of America [1].
Table 2. Patient subsets and sub-stages included into stage III non-small-cell lung cancer
IASLC/UICC 7 Definition TNM subsets Description Robinson
classification
IIIA Incidental N2
(unforeseen N2)
T1–3 N2 N2 found at surgery
Microscopic N2 (final pathology)
Microscopic/macroscopic N2 (frozen section)
IIIA1
IIIA2
IIIA Potentially resectable N2 T1–3 N2 Minimal N2/single station at staging IIIA3
IIIA Potentially resectable N2
But: risk of incomplete resection
T1–3 N2 Pancoast tumour subsets, T3-4 N1, T3 N2 selective
centrally located IIIA(N2)
–
IIIA3
IIIA Unresectable N2 T1–3 N2 Bulky and/or multilevel N2 at staging IIIA4
IIIA Potentially resectable T4
But: risk of incomplete resection
T4 N0–1 Pulmonary artery, carina, spine, trachea, vena cava, right
atrium
–
IIIB Unresectable T4 T4 N0–1
T4 N2
Oesophagus, heart, aorta, pulmonary veins –
IIIB Unresectable N3 T1–4 N3 N3 nodes at staging
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deﬁned as post-operative chemotherapy that is aimed at the
treatment of micrometastases to improve cure rates after curative
complete resection of the tumour at surgery. Neoadjuvant
chemotherapy is deﬁned as preoperative chemotherapy given to
patients that are planned for a curative resection at surgery
(again for improving cure rates by the early treatment of micro-
metastases). The technical advances of radiotherapy allow for
better integration with chemotherapy or surgery [10].
heterogeneity in tumour histopathology
There are data showing that squamous cell carcinoma patients
with stage III disease tend to have a somewhat better overall
survival (OS) prognosis when treated with more aggressive
combined-modality protocols. They also show a trend for more
local and locoregional relapse in comparison with adenocarcin-
oma and large cell carcinoma patients who tend to develop
more systemic relapses (especially an exceptionally high cumu-
lative rate of brain relapse) [11, 12]. However, up to now, this
has not led to different management strategies for these differ-
ent entities.
heterogeneity in tumour location and extension
Large central inﬁltrating primary tumours without lymph node
metastasis (T4N0) have a signiﬁcantly lower tendency to
develop systemic metastatic spread than small tumours with ex-
tensive mediastinal nodal involvement (e.g. T1N3) [13]. These
two entities are characteristic of the remaining wide spectrum in
morphological presentation of patients among the current stage
III disease groups. These morphological differences may poten-
tially represent underlying differences in individual tumour
biology, but the exact cellular mechanisms for this heterogeneity
are still to be determined. The number of involved lymph node
stations and the location of the nodes also inﬂuence the tumour
prognosis [14].
heterogeneity in individual patient risk proﬁle
Long-term smokers (still representing the majority of lung
cancer patients) typically harbour signiﬁcant smoking-induced
comorbidities such as reduced pulmonary function due to
chronic obstructive pulmonary disease, signiﬁcant cardiac pro-
blems related to coronary heart disease and vascular problems
due to smoking-induced arteriosclerosis (peripheral and cere-
bral extension) [15]. Thus, this general proﬁle of cardio-pul-
monary higher risk patients may signiﬁcantly hamper curative-
intent and radical treatment strategies.
inter-institution diversity (technical availability/local
expertise/experience)
Stage III disease curative-intent strategies require considerable
expertise of the staff at the treatment centre. Thoracic surgery
for stage III disease may imply extensive operations including
sleeve resections and resection of locally invaded mediastinal
organs (e.g. trachea, vena cava, vertebra, pericardium, parts of
the right atrium) [16]. Expertise in radiation oncology is needed
to be able to evaluate toxicity/efﬁcacy ratio, specify target
volumes and determine organs at risk and doses that can safely
be delivered. Expert staff are also needed to proceed with
appropriate treatment including proper quality assurance,
bearing in mind that treatment is a multi-modality strategy [10].
in consideration of the guidelines, an individualised decision must
be made within a multidisciplinary team. With this background
of individual risk proﬁles and different morphological tumour
presentation on one hand, and different treatment strategies on
the other, the patient with stage III disease should be discussed
by a multidisciplinary team including pulmonologists, thoracic/
medical oncologists, radiation oncologists and thoracic surgeons
[17]. Closely integrated radiologists and nuclear medicine
physicians for clinical imaging of the tumours, and pathologists
for primary diagnosis and local extension at the time of surgery
(frozen sections) must be available at the individual institution.
due to the complexity of most stage III disease presentations that
require multidisciplinary treatment, management should be
carried out in high-volume centres. High procedure volume is
strongly associated with improved survival after lung cancer
surgery [18]. For other multi-modality treatment strategies
(induction chemotherapy followed by surgery, deﬁnitive
chemoradiotherapy), it is at least possible that high procedure
volume may play a comparably important role. Concerning
radiotherapy, it has been shown that, within clinical trials where
quality assurance of radiotherapy has been implemented,
protocol deviations of radiotherapy delivery were associated
with increased risks of treatment failure and overall mortality
[19]. Another example is Pancoast tumour resection (sulcus
superior tumours) after combined chemoradiotherapy; this
should preferably be carried out in centres with speciﬁc
expertise in the management of Pancoast tumours [20].
results interpretation limited by conduct of trials in highly
selected patient sub-populations. While randomised phase III
clinical trials in stage IV disease and early disease stages I and II
can frequently recruit between 400 and 2000 patients, there are
signiﬁcantly fewer randomised, controlled trials completed in
stage III disease [8, 9]. The majority of randomised trials
deﬁning the standards of care in stage III disease enrolled
between 80 and 500 patients [21–24]. This reﬂects a signiﬁcant
selection bias of patients for inclusion into these randomised
trials [in terms of age, performance status (PS) and stage],
questioning the generalisation of these trial results to each
individual patient presenting with a stage III NSCLC. If we
consider trials that compared sequential versus concomitant
chemotherapy and radiotherapy, they included few patients
older than 70 years of age (only 16%) [25], whereas the median
age for diagnosis of lung cancer is currently 72 years of age.
The gold standard end point in clinical trials is OS.
However, a recent study, based on a re-analysis of randomised
trials having evaluated radiotherapy and chemotherapy contri-
bution in locally advanced and operable NSCLC patients,
investigated a possible correlation between OS and surrogate
end points. It seems to show that disease-free survival can be a
valid surrogate end point for OS in studies of adjuvant chemo-
therapy, and progression-free survival (PFS) could be a valid
surrogate for OS in trials evaluating chemotherapy and radio-
therapy in locally advanced lung cancers [26]. With lung
cancer patients at high risk for comorbidity-related events,
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some investigators also think that cancer-speciﬁc survival
(rarely determined, not yet included in published clinical trials
results) may be a further important surrogate end point for OS
in these stage III disease populations with multiple competing
underlying risks [27].
additional staging systems for stage IIIA NSCLC
Surgical resection remains an important part of the multidiscip-
linary management at least for selected stage IIIA(N2) patients.
Thus, some centres (although overall in decreasing numbers)
still stratify patients according to the ‘Robinson Classiﬁcation of
N2-disease’ (see also Table 2) [28]. This classiﬁcation—besides
the routine TNM staging—may further mirror some of the het-
erogeneities of stage III disease. With deﬁnitive chemoradiother-
apy now being increasingly carried out at several thoracic
institutions, this classiﬁcation has lost some of its former clinical
importance to guide treatment algorithms, but is mentioned
here for historical reasons.
The ESMO 2013 Clinical Practice Guidelines [17] presented a
more practical scheme, integrating CT-scan ﬁndings, the appli-
cation of invasive staging, the categories of N2 disease and the
ensuing treatment strategy (Figure 1). This approach is further
detailed in the ‘incidental IIIA(N2) (unforeseen N2)’ and ‘po-
tentially resectable IIIA(N2) disease’ sections of this document.
how dowe sub-stage stage III NSCLC
for decision making?
Recommendation 1: In the rare cases when stage III disease
patients undergo primary surgical resection, there is a proposed
deﬁnition of a surgically complete resection. In the majority of
patients where stage III disease is conﬁrmed by initial staging
investigations, it is still of importance to classify them at base-
line as resectable (1), potentially resectable with an increased
risk for incomplete resection (2) or unresectable (3).
In the rare cases where patients are initially taken to surgery
and are resected and found to have stage III NSCLC, complete
resection is pathologically deﬁned by the conﬁrmation of
negative surgical margins in the resected specimen, including
the highest mediastinal node negativity at the time of resecting
surgery and/or mediastinal lymph node dissection [29].
Difﬁculty in assessing extra-capsular lymph node extension
upfront has a comparable impact on positive resection
margins [14, 30, 31]. The majority of patients in stage III,
however, will be found to have stage deﬁning extension (e.g. T,
N) in the initial imaging and invasive staging investigations.
Since the possibility of complete resection is an outcome par-
ameter with major impact on the overall prognosis of the
patient, the multidisciplinary panel including radiologists,
pulmonologists and thoracic surgeons should classify the
patient upfront as either clearly potentially resectable (1),
potentially resectable as part of an intermediate group (2) or
deﬁnitely unresectable (3). In the intermediate group, resec-
tion is deemed to have an underlying increased risk of an in-
complete resection. Here, typically tumours of the superior
sulcus (Pancoast) and speciﬁc centrally located tumours (T3/
T4 involvement) can be identiﬁed [13, 32]. Evaluating and
predicting these parameters upfront is key for adequate plan-
ning of the deﬁnitive local treatment without treatment inter-
ruptions (either surgery, a neoadjuvant chemotherapy or
No enlarged LNs
and peripheral
tumour
No enlarged N2
nodes but central
tumour or hilar
LNs
N0–N1
N2
N3Enlarged discrete
N2 LNs
Extensive
mediastinal N2
infiltration
1
 Category discription according to CT imaging as in ACCP staging document (Chest 143 Suppl 5:211S-250S, 2013),
   see text for more details.
2
 See text for factors involved in the choice between non-surgical and surfical multimodality treatment.
Unresectable
N2Not required
INVASIVE
LN RESULT
CATEGORY
OF N2
THERAPEUTIC
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Surgery:
unforeseen N2
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multidisciplinary
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Non-surgical
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IMAGING:
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Figure 1. Suggested algorithm for treatment in patients with logoregional non-small-cell lung cancer, based on imaging, invasive lymph node staging tests
and multidisciplinary assessment. Reproduced from [17], by permission of Oxford University Press, on behalf of ESMO.
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chemoradiotherapy approach, as deﬁned by an initial combin-
ation chemotherapy given before any deﬁnitive local therapy
such as surgery or primary deﬁnitive radiation/chemora-
diotherapy), because of its complexity and the risk that a
wrong decision may result in an unsuccessful outcome. This
could lead to palliative treatment (e.g. an incomplete resection
after preoperative concurrent chemotherapy and radiotherapy
to a dose of 45 Gy).
what is the optimal diagnostic work-up
for stage III NSCLC patients?
positron emission tomography–computed
tomography
Recommendation 2.1: All patients planned for deﬁnitive stage
III NSCLC treatment should undergo a diagnostic high-
resolution CT followed by a PET or a combined positron emis-
sion tomography–computed tomography (PET-CT) with a CT
technique with adequately high resolution for initial staging
purposes [I, A] in order to rule out detectable extra-thoracic
extra-cranial metastasis and to assess potential mediastinal
lymph node involvement, ideally within 4 weeks before the
start of treatment [III, B]. Single PET-positive distant lesions
need pathological conﬁrmation [V, B].
Several randomised trials have investigated the diagnostic
impact of whole body PET-CT for initial staging of stage III
NSCLC patients [33–37]. This investigation may rule out extra-
cerebral metastases before decision making for any local treat-
ment with a curative intent. Mediastinal lymph node staging
may be initiated by this method [34]. Further pathological con-
ﬁrmation of suspected lymph node stations should follow using
endoscopic bronchial ultrasound (EBUS), endoscopic ultrasound
(EUS), cervical mediastinoscopy or video-assisted thoracoscopy
(VATS) investigations including video-assisted mediastinoscopy
(VAMS) or video-assisted mediastinal lymphadenectomy [38–
41]. Single PET-positive distant lesions need pathological con-
ﬁrmation before accepting stage IV clinical staging status for
any patient [6]. The quality of the local CT component in this
setting is critical. Only the most modern generation of PET-CT
scanners have high-resolution CT scanners embedded into
the investigation. A high-enough-resolution CT scan for initial
imaging evaluation of the primary tumour and the mediastinal
organs should not be skipped for a less diagnostically accurate
conventional CT scan.
(minimally) invasive mediastinal staging (1) (trans-
bronchial needle aspiration /EBUS/EUS/
mediastinoscopy)
Recommendation 2.2: PET-positive mediastinal ﬁndings
should be pathologically assessed [I, A]. Invasive mediastinal
staging may still be indicated despite PET negativity in case of
suspicious lesions (primary tumour of >3 cm large axis,
central tumours, cN1, CT-enlarged lymph nodes with small
axis >1 cm) [III, B].
Endoscopic methods should be preferred as the initial interven-
tional procedure whenever feasible [I, A]. In case of negative
endoscopic ﬁndings, and high suspicion of mediastinal node in-
volvement, surgical staging is indicated [I, A].
PET-positive mediastinal ﬁndings should always be conﬁrmed
cytologically or histologically, preferably at ﬁrst by minimally in-
vasive mediastinal staging. Methods available include trans-
bronchial needle aspiration, guided by EBUS or oesophageal
EUS [35, 38–41]. PET-CT has a high negative predictive value
but its positive predictive value is not so widely accepted [37,
38]. Therefore, if signiﬁcant impact on the overall treatment
strategy is assumed, which is the case with most stage III
NSCLC, PET-positive mediastinal ﬁndings should be patho-
logically assessed. If mediastinal nodes are PET-negative but
suspicion of tumour involvement remains (criteria: primary
tumour of 3 cm large axis, central tumours, cN1, CT-enlarged
lymph nodes with their small axis 1 cm), there may still be an
indication for minimally invasive mediastinal staging investiga-
tions in the form outlined above [37, 38].
Following PET-CT investigations, endoscopic methods re-
present the easiest interventional procedure [37]. If the results of
these diagnostic procedures are negative despite a high suspicion
of mediastinal node involvement, surgical staging of the medias-
tinum is clearly indicated [35]. If surgical staging of the medias-
tinum is indicated, VAMS is the preferred technique for upper
mediastinal lymph nodes and VATS is preferred for aorto-
pulmonary lymph nodes [35].
brain MRI/brain CT
Recommendation 2.3: All patients planned for curative stage
III NSCLC treatment should receive brain imaging for initial
staging [III, B]. Contrast-enhanced brain MRI is the preferred
method for staging of the brain in stage III disease [III, A].
Alternatively, dedicated contrast-enhanced brain CT can be
carried out [III, B].
Patients with locally invading T4 tumours and N2 or N3 me-
diastinal nodal involvement have an underlying high risk of
primary brain metastases [42, 43]. Therefore, if curative de-
ﬁnitive treatments are planned for these patients, initial
staging of the brain with adequate imaging methods should
generally be carried out [44]. The method of choice is con-
trast-enhanced brain MRI. Contrast-enhanced brain CT can
be carried out as a valid alternative in case of contraindica-
tions to MRI or unavailability. Some studies have shown an
adequate positive predictive value for this method but its
quality may vary from centre to centre and needs further crit-
ical evaluation [45].
what are the most relevant comorbidities
assessed in the clinical work-up of stage
III NSCLC patients?
Recommendation 3.1: Cardio-pulmonary functions are rele-
vant for multidisciplinary treatment decisions including
surgery [II, A] or radiotherapy [III, C].
Patients for whom a surgical intervention is planned must be
functionally assessed for surgery. This includes adequate cardio-
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pulmonary function testing. Guidelines for these evaluations
have been published by the European Respiratory Society (ERS)
[15]. Cardiac function may be investigated by electrocardiogram
(ECG), echocardiography, stress ECG, stress echocardiography
or even coronary angiography including left ventricular cath-
eterisation, in selected cases [15]. Pulmonary function testing
includes spirometry and diffusion capacity of the lung for
carbon monoxide, split function studies (especially perfusion
scintigraphy) and exercise tests (in particular, peak oxygen con-
sumption) [15]. With a speciﬁc lung resection planned at
surgery, lung function parameters can be predicted for the post-
operative setting following assumed lobectomy as well as pneu-
monectomy [15]. These parameters have been standardised and
are important in evaluating patients ﬁt for radical (curative) sur-
gical treatment. The ERS consensus group has also made some
proposals for patients planned for curative radiotherapy and
chemoradiotherapy approaches [15]. Unfortunately, currently
post-radiotherapy lung function cannot be readily predicted
taking into account the planned treatment volumes. There is
indeed a lack of data on the inﬂuence, if any, of pulmonary
function tests on radiation-induced lung toxicity, the interplay
between pre-existing comorbidities and systemic treatments and
possible adverse effects [10]. More prospective data are war-
ranted on the toxicity and outcome of chemoradiotherapy.
Many studies, mostly retrospective, have addressed the relation-
ship between dose and volume to organs at risk, such as normal
lung, heart, oesophagus and spinal cord, in predicting the prob-
ability of radiation-induced damage. Some of these studies have
included patient factors [46, 47]. In conformal radiotherapy,
dose volume histograms (DVH) to the tumour and nodal
volume, as well as organs at risk, contribute to determining the
optimal treatment plan for each individual patient. Dose con-
straints have thereby been deﬁned according to DVH para-
meters and several normal tissue complication probability
models in the clinic, and are also being used in prospective
studies [47, 48]. No robust data are, however, currently available
linking DVH data to heart toxicity.
Recommendation 3.2: Comorbidities are of paramount import-
ance since the potential risk of toxicity/morbidity/mortality
has to be balanced with the potential beneﬁt of any aggressive
curative-intent treatment strategy [III, A].
The comorbidity proﬁle of the patients has to be critically ana-
lysed before any curative-intent treatment decision in stage III
disease [49, 50]. This includes deﬁnitive surgery on one hand,
but also deﬁnitive chemoradiotherapy on the other. Signiﬁcant
toxicities during aggressive treatment can be observed following
a history of recent vascular events of the patient, such as myo-
cardial infarction or stroke (e.g. within the last 6 months before
treatment). Further signiﬁcant comorbidities are represented by
renal insufﬁciency or necessary haemodialysis that may create
difﬁculties at the time of chemotherapy or surgery. Heart failure
and cardiac rhythm disorders must be critically acknowledged—
as well as diabetes mellitus, which must be treated adequately
before any local treatment. Frequently used scores include
the Charlson Comorbidity Index (CCI) in either the full or an
abridged, simpliﬁed version [50, 51]. However, the ERS recom-
mends the use of the full version of the CCI for better compar-
ability of the datasets. Evaluation of comorbidities is included in
a comprehensive geriatric assessment for elderly patients [49].
Insufﬁcient prospective evidence has been generated to reliably
disqualify a patient from radical treatment based on one of these
scores, and further prospective studies are urgently needed.
Recommendation 3.3: For curative-intent management,
patients should be able to undergo platinum-based chemother-
apy (preferably cisplatin) [I, A].
Both for (neo-)adjuvant chemotherapy coupled with complete
resection in stage IIIA disease as well as for concurrent or se-
quential chemoradiotherapy protocols in stage III disease, the
patients should be able to undergo platinum-based chemother-
apy [8, 9, 24]. Concurrent chemoradiotherapy is deﬁned as
simultaneous (same-day) administration of an active chemo-
therapy in parallel to ongoing thoracic radiotherapy fractions.
Sequential chemoradiotherapy is deﬁned as giving upfront
combination chemotherapy for several cycles followed by a
block of fractionated radiotherapy only (for 5–7 weeks). The
clearest evidence exists for cisplatin-based doublets (cisplatin
and etoposide or cisplatin and vinorelbine or other vinca alka-
loids). This has been sufﬁciently demonstrated by the Lung
Adjuvant Cisplatin Evaluation (LACE) meta-analysis [8].
Cisplatin can be easily administered to the majority of patients
excluding only those few with signiﬁcant renal failure or heart
failure [52, 53].
what are the optimal multi-modality
combinations for the different stage III
disease sub-stages?
incidental IIIA(N2) (unforeseen N2)
Recommendation 4.1: If, despite adequate mediastinal staging
procedures, N2 disease is only documented intra-operatively,
surgery should be followed by adjuvant chemotherapy [I, A].
In case of complete resection, addition of post-operative radio-
therapy is not routinely recommended, but may be an option
following individual risk assessment [V, C].
Patients that were classiﬁed as having stage I or stage II disease in
the staging investigations but are found to have an incidental
intra-operative N2 diagnosis [old classiﬁcation: microscopic N2-
involvement (ﬁnal pathology) Robinson IIIA1 and microscopic/
macroscopic N2-involvement (frozen section) IIIA2] have a rela-
tively good prognosis and must be considered for adjuvant
chemotherapy (Table 2, Figure 1) [8] . Adjuvant chemotherapy is
deﬁned as chemotherapy, given after the complete resection of a
resectable tumour, to reduce relapse based on micrometastases.
These patients typically cannot be identiﬁed upfront and pre-
operatively as having stage III disease. There is an ongoing discus-
sion about adjuvant post-operative radiotherapy for these patients
and, therefore, an ongoing European trial (LungART) is evaluat-
ing this strategy [54]. Retrospective analysis from randomised
trials and from a SEER database analyses suggest a potential
beneﬁt of adjuvant radiotherapy in N2 disease [55–57]. Even
though it is unclear whether modern adjuvant post-operative
radiotherapy may have an impact on the outcome of such patients,
if the individual assessment of locoregional risks shows a high
probability of local failure, post-operative radiotherapy may be a
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valid option. It should then be delivered after adjuvant chemother-
apy, as concurrent post-operative chemoradiotherapy is not rou-
tinely recommended [58]. Patients who have been incompletely
resected with an R1 (microscopic) or R2 (macroscopic) resection
specimen result should be discussed individually in the multidis-
ciplinary panel. Post-operative thoracic radiotherapy or even, in
rare cases, concurrent chemoradiotherapy protocols may be an
option for some of these patients but no clear guideline currently
exists since the number of these patients is extremely small. For
decision making, it is probably best to weigh the risks of locoregio-
nal relapse against the risk of systemic relapse in the individual
patient. With better and more critical selection for stage III disease
patients to undergo surgical measures the percentage of incom-
plete resections can be kept sufﬁciently low.
potentially resectable IIIA(N2) disease
preoperative diagnosis of IIIA(N2)
Recommendation 4.2.1: Possible strategies include several
options: induction chemotherapy followed by surgery, induc-
tion chemoradiotherapy followed by surgery, or concurrent de-
ﬁnitive chemoradiotherapy [I, A]. No recommendation can yet
be made; however, an experienced multidisciplinary team is of
paramount importance in any complex multi-modality treat-
ment strategy decision. If induction chemotherapy alone is
given preoperatively, post-operative radiotherapy is not standard
treatment but may be an option based on critical evaluation of
locoregional relapse risks [IV, C].
In patients with preoperatively conﬁrmed IIIA(N2) disease
based on the staging investigations carried out, different multi-
modality treatment strategies can be envisaged, including induc-
tion chemotherapy followed by surgery [22, 59–64], induction
chemoradiotherapy followed by surgery, or deﬁnitive chemora-
diotherapy protocols [24, 65–74] (Table 2, Figure 1). Only full-
dose, deﬁnitive concurrent chemoradiotherapy versus induction
concurrent chemotherapy and radiotherapy followed by surgery
has been investigated in a prospective randomised North
American Intergroup trial, in which patients had to have histo-
or cytologically proven N2 disease and for whom deﬁnitive che-
moradiotherapy was to be considered the standard approach
(comparator arm of this study) [23]. Patient selection for this
multicentre randomised trial included patients that were evalu-
ated to be potentially resectable with stage IIIA(N2) disease. No
difference in OS by intent to treat analysis but a better PFS for
patients with surgery was observed [23]. It is the general percep-
tion that both treatment strategies remain possible options in
this situation based on the ﬁnal results of this clinical trial.
However, toxicity of surgery in the local treatment centre setting
remains a signiﬁcant issue. In the Intergroup study, 54 of the
155 resections were pneumonectomies; 14 patients treated with
pneumonectomy died within 30 days after surgery. An observed
26% mortality rate in the right-sided pneumonectomy patients
is signiﬁcantly higher than what is generally considered accept-
able for this procedure and, also, has not been seen and reported
by experienced thoracic centres in Europe, North America and
Asia. A recent analysis, systematic review and meta-analysis
of perioperative mortality after neoadjuvant therapy and
pneumonectomy for NSCLC revealed an overall 30-day mortal-
ity of 7% among the 27 published studies included in the review
which is signiﬁcantly less reported toxicity than in the multicen-
tre North American study—predominantly after pneumonec-
tomy [75–78].
Other centres have carried out large trials with induction
chemotherapy followed by surgery, or by deﬁnitive chemora-
diotherapy without surgery, with more or less comparable OS
data [21, 22, 24, 60–65].
The EORTC study also required upfront cytological or histo-
pathological proof of N2 disease in a group of patients deﬁned
as unresectable per protocol [22]. Patients received three cycles
of induction chemotherapy treatment—18 different chemo-
therapy protocols were included—and those who showed any
response (complete, partial or minor) to induction were rando-
mised either to surgical resection or deﬁnitive radiotherapy.
Patients included into this trial were most likely in advanced
IIIA(N2) disease as only 50% of the patients could be rando-
mised following induction [22]. No difference was noted
between the two randomisation arms in either OS data of both
arms or PFS results. The patient population of this study is
probably not directly comparable with the one included into the
Intergroup trial, which makes combined analysis of these two
trials very difﬁcult. The selection procedure of the EORTC study
with upfront induction chemotherapy was probably responsible
for the upfront more advanced stage IIIA(N2) population.
Another criticism of this study is that the comparator arm was
radiotherapy alone and not concurrent chemoradiotherapy.
This, furthermore, makes the ﬁnal impact of its outcome
difﬁcult to bring into perspective with the more standard con-
current chemoradiotherapy strategies for these patients in the
present day.
A recent study by the Swiss Group (SAKK) was presented at
ASCO in 2013 [79] and at ESMO in 2014 [80]. The study
included patients with cytologically or histologically proven IIIA
(N2) disease and randomised to induction chemotherapy fol-
lowed by surgery versus induction chemotherapy followed by
radiotherapy and then deﬁnitive surgery. Both the primary
end point of the trial (OS) as well as the secondary end point
(PFS) showed no signiﬁcant differences between the arms. It is
noteworthy that the employed induction chemotherapy proto-
col was cisplatin and docetaxel. Since a high percentage of
patients could be taken to surgery following induction chemo-
therapy alone, the patient selection of this study included more
potentially resectable IIIA(N2) disease patients and the induc-
tion chemotherapy turned out to be quite effective in inducing
downsizing and downstaging.
Based on these different trials results, it is the general percep-
tion that, in these complex treatment situations, the overall ex-
pertise of the multi-modality team at the treatment centre is
probably of more importance for the overall outcome of the
patient than the exact schedule and permutation of the multi-
modality treatment protocol [17]. It should be outlined that
such treatment should preferably be decided upfront, in the
presence of an experienced thoracic surgeon, respecting the
delay of 4 weeks between the end of radiotherapy and surgery
and the fact that any split in the radiotherapy application has to
be avoided, if possible.
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potentially operable IIIA(N2) disease and selected IIIB disease—
but at high risk of incomplete resection
Recommendation 4.2.2: In potentially resectable superior
sulcus tumours, concurrent chemoradiotherapy induction fol-
lowed by deﬁnitive surgery is the treatment of choice [III, A].
The same strategy may be applied for potentially resectable T3
or T4 central tumours in highly selected cases and experienced
centres [III, B]. In both situations, surgery should be carried
out within 4 weeks after the end of radiotherapy [III, B].
For potentially resectable superior sulcus tumours, concurrent
chemoradiotherapy induction followed by surgery has become
the standard of care [81] (Table 2, Figure 1). As randomised
trials are difﬁcult to perform because of rarity of these tumours,
this recommendation is based on a multicentre prospective
phase II Southwest Oncology Group (SWOG) trial in North
America, which demonstrated an excellent complete resection
rate and markedly improved 5-year survival rates [81]. A com-
parable strategy using concurrent chemoradiotherapy to down-
size the primary tumour and down-stage centrally located
tumours may be applied to certain T3 N2 or T4 N0-1 tumours
[28, 29, 66–69]. Several groups have reported excellent complete
response and long-term survival rates following such induction
therapy in these IIIA and selected IIIB subset [28, 29, 66–69].
Recently, a German Group presented a pilot phase II trial
and a randomised phase III trial looking at surgery versus de-
ﬁnitive chemoradiotherapy boost following complex induction
chemotherapy and concurrent chemoradiotherapy (ESPATÜ)
[66, 82]. No beneﬁt in OS and PFS for surgical resection was
noted in this trial but both study arms showed excellent long-
term survival results. The patient subsets of this study included
one-third potentially resectable IIIA(N2) disease patients and
one-third centrally located T4N0-1, both groups with under-
lying risks for incomplete resection. The best results for the
patients in this study were noted in the T4N0–1 subset [now
stage IIIA (IASLC/UICC 7th edition)].
unresectable IIIA (N2) disease and IIIB disease
patients
Recommendation 4.3: Concurrent chemoradiotherapy is the
treatment of choice in patients evaluated as unresectable in
stage IIIA and IIIB [I, A]. If concurrent chemoradiotherapy is
not possible—for any reason - sequential approaches of induc-
tion chemotherapy followed by deﬁnitive radiotherapy re-
present a valid and effective alternative [I, A].
This group includes both unresectable IIIA(N2) disease based
on bulky and multiple mediastinal nodal involvement and IIIB
disease based on unresectable T4 involvement or any N3-
disease in the mediastinal nodes (Table 2, Figure 1). For these
patient groups, deﬁnitive radiotherapy and chemotherapy com-
binations remain the treatments of choice. Concurrent chemor-
adiotherapy generally gives signiﬁcantly better OS results than
sequential chemotherapy and radiotherapy protocols in unre-
sectable IIIA and IIIB disease [21–24, 83–86]. This is based on
several phase III trials and a meta-analysis based on individual
patient data [25]. There was a signiﬁcant beneﬁt of concomitant
chemoradiotherapy on OS with an absolute beneﬁt of 4.5% at 5
years [hazard ration (HR) 0.84; P = 0.004]. These trials were
carried out with presently outdated staging methods and mostly
2D radiotherapy techniques.
Patients who are considered to be unﬁt for concurrent chemo-
therapy and radiotherapy can be treated with induction chemother-
apy and high-dose radiotherapy with curative intent [87–90].
Accelerated radiotherapy may be beneﬁcial in this situation [91–93]
as it has shown superior results [90, 92]. Also, the results of an indi-
vidual-patient-data-based meta-analysis for non-concurrent che-
moradiotherapy further support this individualised strategy [92].
Few groups have piloted surgery after combined-modality
approaches in N3-disease patients—mostly chemoradiotherapy.
There is old phase II data from SWOG and from the West
German Cancer Centre Group and from several other investiga-
tions looking at this subset [65, 67–69]. In the ESPATÜ trial
presented at ASCO 2014, one-third of the patient group
included patients with T1–3N3 disease with N3 proven and
found at staging mediastinoscopy [82]. Long-term survival was
also noted in both arms of this patient subset. The other groups
having explored surgical resection for selected N3 patients after
induction chemoradiotherapy also noted promising results, but
this could be related to patient selection and no ﬁnal evaluation
of this treatment strategy can currently be given [65–69, 82].
Concurrent chemoradiotherapy remains the treatment of choice
for these patient groups outside speciﬁc expertise generated by
the treatment group or well-designed clinical trials.
prophylactic cranial irradiation
Recommendation 4.4: There is currently no role for prophylac-
tic cranial irradiation in stage III NSCLC [II, A].
Relapse pattern in stage III NSCLC patients has shown a high cu-
mulative risk of developing brain metastases [42, 43]. Several trials
have explored prophylactic cranial irradiation (PCI) within the
multi-modality strategy. A signiﬁcant impact on brain relapse as
ﬁrst site of failure and on overall-brain relapse rate has clearly been
demonstrated [42]. However, a recent large Radiation Therapy
Oncology Group (RTOG) phase III trial addressing the issue of PCI
in stage III disease patients treated with multi-modality therapy was
not able to demonstrate a signiﬁcant impact on OS by PCI versus
observation [94]. This trial closed prematurely because of poor
accrual; although it was underpowered, it showed that PCI could de-
crease the rate of brain metastases. Other trials are open to accrual.
what is the optimal chemotherapy to be
given to stage III disease patients?
cisplatin or carboplatin in combination with
radiotherapy
Recommendation 5.1: In the absence of contraindications, the
optimal chemotherapy to be combined with radiation in stage
III NSCLC should be based on cisplatin. There are no ﬁrm
conclusions supporting single agent carboplatin as a radiation
sensitiser [I, A].
For ﬁt patients with inoperable stage III NSCLC, cisplatin-based
chemotherapy given concurrently to radiation therapy is recom-
mended [24]. According to level I evidence-based medicine,
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cisplatin may be combined with etoposide, vinorelbine or other
vinca alkaloids [24, 25]. However, in some patients, based on
speciﬁc comorbidities, other treatment modalities may alterna-
tively be considered: single-agent cisplatin or carboplatin-based
chemoradiotherapy, sequential chemotherapy and radiotherapy
or even radiotherapy alone. These alternatives can be proposed
to patients with higher risks of infection, general or pulmonary
complications. There are already randomised clinical trials
showing the efﬁcacy of single-agent cisplatin delivered concomi-
tantly with radiotherapy [85, 95, 96]. On the contrary, single-
agent carboplatin has failed to improve survival when given
concurrently with radiotherapy in two prospective randomised
trials [96, 97]. Recently, an Asian randomised clinical trial com-
paring radiotherapy alone with combination of daily single-
agent carboplatin and radiotherapy in elderly patients >70 years
of age has shown that combined chemoradiotherapy could
improve outcome in a selected group [98]. However, relatively
signiﬁcant haematological toxicity was reported. As these data
focus on elderly Asian populations, some experts think that
further safety data should be collected in Caucasian patients
before implementing this approach as a routine schedule, only
for high-risk patients with signiﬁcant comorbidities. The major
criticism against this trial however, is that even in elderly
patients, standard treatment should be a platinum-based
doublet given concurrent to radiotherapy. Age alone is not an
argument against a curatively intended protocol.
Several North American studies have used the weekly carbopla-
tin and paclitaxel regimen concomitantly with radiotherapy with
conﬂicting results. Despite this regimen having served as a stand-
ard comparator regimen in large clinical trials in North America
and also in some parts of Europe and Asia, it is not accepted by all
physicians in these regions [83, 99, 100]. Moreover, such a com-
bination remains an accepted and valid option for patients who
cannot receive cisplatin-based chemotherapy because of existing
signiﬁcant comorbidities. If low-dose weekly chemotherapy sche-
dules are used in the concurrent treatment phase, it is highly
recommended to use a full-dose platin doublet given either before
or after the radiotherapy application.
chemotherapy combination
Recommendation 5.2: Most comparative studies of concurrent
chemoradiotherapy versus sequential administration were using
cisplatin + etoposide or cisplatin + vinca alkaloid (typically:
cisplatin + vinorelbine). There are no comparative phase III trials
using the paclitaxel/carboplatin regimen. When delivered peri-
operatively, cisplatin-based combinations are considered the
treatment of choice, in the absence of contraindications [I, A].
Several randomised trials comparing concurrent and sequential
chemoradiotherapy were included in the individual-patient-data-
based meta-analysis [21, 24–26]. The North American trial using
cisplatin and vinblastine is interpreted as a study demonstrating
the superiority of the concurrent strategy [24]. The small Czech
randomised study compared the more modern cisplatin and
vinorelbine doublet and showed a beneﬁt for the concurrent strat-
egy [85]. The West Japan Lung Cancer Group study (although
strongly supporting concurrent chemoradiotherapy) was based
on a mitomycin C combination, now rarely used because of
potential lung toxicity described in earlier observations [21, 76].
In the Japanese study, split-dose radiation was used—a strategy
that would not be supported by modern radiation biology consid-
erations [101]. The French trial used cisplatin and etoposide and
favoured the concurrent administration with manageable toxicity
[84]. The survival beneﬁt induced by a platinum-based concomi-
tant strategy has been emphasised in an individual-patient-data-
based meta-analysis [25, 86]. Even if carboplatin–paclitaxel-based
chemoradiotherapy is frequently used, especially in North
America, it should be underlined that no carboplatin–paclitaxel-
based regimen was evaluated in any of the individual-patient-data
meta-analyses [25]. There is one underpowered randomised
phase II study that compared a carboplatin and paclitaxel com-
bination directly to a cisplatin-based combination, for which the
results favoured the cisplatin–etoposide combination in terms of
survival [87]. This leads to the consensus that cisplatin-based
doublets should be preferred in stage III disease multi-modality
protocols when treatment has a curative intent.
number of chemotherapy cycles
Recommendation 5.3.1: In the stage III disease chemoradiother-
apy strategy, two to four cycles of concomitant chemotherapy
should be delivered [I, A]. There is no evidence for further induc-
tion or consolidation chemotherapy. In the perioperative setting,
three to four cycles of cisplatin-based chemotherapy are recom-
mended [I, A], aiming at a total cumulative dose of at least 300
mg/m2 of cisplatin in the adjuvant setting [II, B].
The majority of randomised clinical trials in stage III NSCLC
patients treated by concurrent chemoradiotherapy used two to
four cycles of cisplatin-based combination chemotherapy [25].
Based on adjuvant chemotherapy in stage II and stage III
disease, four cycles of cisplatin-based combination chemother-
apy are deﬁned as the standard of care [8]. In the LACE adju-
vant meta-analysis, one of the main prognostic factors was the
delivery of a cumulative cisplatin dose >300 mg/m2 [8].
Recommendation 5.3.2: Regarding stage III disease chemora-
diotherapy, two to four cycles of concomitant chemotherapy
should be delivered [I, A].
There is no evidence for extended induction or consolidation
beyond these three to four cycles [99, 100].
In operable patients, in the large randomised phase III
Intergroup trial 0139, the comparative arm used four cycles of
cisplatin and etoposide given together with thoracic radiother-
apy at a dose of 61 Gy. This serves as a landmark study in oper-
able stage III(N2) disease [23]. In this study, two cycles were
given as consolidation following the deﬁnitive chemoradiother-
apy protocol (in 75% of patients).
what is the optimal radiation regimen
given to stage III NSCLC patients?
dose and fractionation in concurrent
chemoradiotherapy
Recommendation 6.1.1: 60–66 Gy in 30–33 daily fractions is
recommended for concurrent chemoradiotherapy [I, A].
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Maximum overall treatment time should not exceed seven
weeks [III, B]. ‘Biological intensiﬁcation’, such as treatment ac-
celeration, is not standard practice in concurrent chemora-
diotherapy schedules [III, B].
The majority of clinical concurrent chemoradiotherapy regimens
in stage III NSCLC have used 60–66 Gy cumulative radiotherapy
doses in conventional daily fractions of 1.8–2.0 Gy [24, 84–86]. A
detailed look at the relationship of overall treatment duration and
outcome in these studies has conﬁrmed that prolonged treatment
time is a critical issue in this setting, as it is in other tumour types
[92]. The RTOG 0617 study has conﬁrmed that radiation dose es-
calation (with conventional 2 Gy per fraction regimen leading to a
prolonged treatment time exceeding seven weeks) and concurrent
CT is not the way forward. In this phase 2 × 2 factorial design
phase III randomised, controlled trial, patients with stage III
NSCLC were randomised to receive high-dose (74 Gy in 37 frac-
tions) or standard-dose (60 Gy in 30 fractions) radiotherapy con-
currently with weekly paclitaxel/carboplatin with or without
cetuximab [83]. In a planned interim analysis after 90 events, the
high-dose arms were closed for futility. At a median follow-up
time of 22.9 months, survival of 419 eligible patients was signiﬁ-
cantly inferior with high-dose compared with standard-dose radio-
therapy; median OS was 28.7 months [95% conﬁdence interval
(CI) 24.1–36.9] for patients who received standard-dose radiother-
apy and 20.3 months (17.7–25.0 months) for those who received
high-dose radiotherapy (HR 1.38, 95% CI 1.09–1.76; P = 0.004).
However, treatment intensiﬁcation should not be abandoned in
stage III NSCLC. This is an area of active research, facilitated by
the rapid development of advanced radiotherapy techniques.
dose and fractionation in sequential
chemoradiotherapy
Recommendation 6.1.2: Promising outcome is achieved with
accelerated radiotherapy [I, A]. A potential radiation schedule
could be the delivery of 66 Gy in 24 fractions [II, C].
Accelerated radiotherapy has resulted in improved 5-year survival
rates compared with so-called conventional radiation schedules, i.e.
2 Gy per day ﬁve times per week [53, 90, 92]. The CHART
regimen serves as a good example that was investigated in a large
phase III trial in a few stage II disease and mostly stage III disease
patients and resulted in a signiﬁcant survival beneﬁt when com-
pared with conventionally fractionated treatment application [53].
Even today, this treatment protocol is selectively used in several
European centres, especially in the UK where it was initially
piloted. Apart from multiple fractions per day schedules, an accel-
erated high-dose regimen was investigated in one phase II study
and one phase III study of 66 Gy in 24 daily fractions [90]. These
speciﬁc schedules represent valuable alternatives in patients where
concurrent chemoradiotherapy protocols may not be possible
because of comorbidity proﬁle issues and expected toxicities.
radiation doses in the preoperative setting
Recommendation 6.1.3: Standard preoperative radiation doses
within chemoradiotherapy protocols should be between 40 and
50 Gy in conventional fractionation or 40–45 Gy in accelerated
fractionation (bid application) [I, B].
The majority of clinical trials that have given preoperative chemora-
diotherapy have used 40–50 Gy cumulative doses in conventional
fractionation of 1.8–2.0 Gy per day. Several groups have also
employed accelerated hyper-fractionation given as 1.5 Gy twice
daily up to 40–45 Gy. These regimens have been used within
larger phase II and randomised multicentre phase III studies.
Furthermore, some investigators have piloted higher radiation
doses up to 60–63 Gy in conventional fractionation, but this has
only been done within the phase II setting. As increased preopera-
tive toxicities (also described in the literature) may result from these
treatment intensiﬁcations (e.g. radiation pneumonitis, acute respira-
tory distress syndrome), it is advisable to give these higher doses
only in the setting of prospective controlled clinical trials. Higher
preoperative radiation doses may result in higher pathological com-
plete remission rates and may potentially optimise preoperative
downsizing and down staging but these advantages must be careful-
ly weighed against the potentially higher resulting toxicities.
elective mediastinal nodal irradiation
Recommendation 6.2: Elective mediastinal nodal irradiation—
prophylactic irradiation of non-involved mediastinal nodes—is
not recommended [I, B].
Prophylactic irradiation of non-involved mediastinal nodes is no
longer recommended when using modern diagnostic and che-
moradiotherapy strategies, neither in sequential nor in concurrent
chemoradiotherapy [102]. Microscopic disease at this level is
assumed to be treated by systemic chemotherapy combined with
radiation. However, selective nodal irradiation can only be recom-
mended when at least a ﬂuorodeoxyglucose (FDG)–PET-CT scan
is available and shows signs of locoregional extension. Adequate
mediastinal staging is, therefore, also recommended in non-surgi-
cal patients targeted for treatment with curative intent [91].
radiotherapy technique
Recommendation 6.3: Quality assurance and dose constraints
are required as a prerequisite [I, A].
It is recommended that high-dose radiotherapy is prepared and
executed according to standards such as those of the European
Organisation for Research and Treatment of Cancer (EORTC)
[10]. More and more centres use respiration-correlated CT
scans (or ‘4D CT’), so as to take into consideration tumour
movement in thoracic oncology [103, 104]. Respiratory gating
and tumour movement adaptations, as well as intensity-modu-
lated radiotherapy, are important points for further improve-
ment of targeting radiation delivery to the primary tumour and
involved nodes [103, 104]. However, these treatment modalities
are not yet used at all treatment centres.
what is the optimal surgical management
in resectable stage III NSCLC patients?
type and extent of surgery
Recommendation 7.1: The optimal surgical management aims
at complete resection—preserving as much non-involved par-
enchyma as possible, preferably carried out by lobectomy/
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sleeve resection [I, A]. Complete resection necessarily includes
systematic mediastinal nodal exploration. In selected patients,
pneumonectomy must be carried out, but should be adequately
selected and the procedure restricted to experienced centres
[III, B].
Curative surgery in stage III disease will preferably include surgi-
cal techniques such as lobectomies, bi-lobectomies and sleeve
resections, to spare lung tissue as much as possible [77].
Nevertheless, in recent years, it has become clear that in selected
patients, complete resection will require a pneumonectomy or,
in some cases, a sleeve pneumonectomy, which can be safely
conducted in experienced high-volume centres [75, 77, 78].
post-operative mortality related to surgical
intervention
Recommendation 7.2: Based on reported series, post-lobectomy
and pneumonectomy mortality rates should not exceed 2%–
3% and 3%–5%, respectively [IV, B].
Post-operative mortality resulting from stage III disease surgical
resections should be evaluated in every thoracic centre. Modern
published series show that surgical 30-day mortality ranges
between 2%–3% for lobectomy and 3%–8% for pneumonectomy
[77, 78]. Importantly, it has been recognised that there is a sig-
niﬁcant relationship between volume and outcome in surgery of
lung cancer, supporting the notion that these procedures should
be restricted to experienced centres [78].
do patient characteristics contribute to
treatment decisions in stage III NSCLC?
age
Recommendation 8.1: Age itself has not been shown to inﬂu-
ence outcome following surgery plus adjuvant chemotherapy
or deﬁnitive concurrent chemoradiotherapy [I, A]. However,
data are limited for the elderly population and, in particular,
in patients above 75 years of age.
Age alone is not a good parameter to predict outcome in stage III
disease after surgery and adjuvant chemotherapy. Due to the
small numbers, an exploratory analysis of the randomised trial
from the National Cancer Institute of Canada in patients over 80
years failed to demonstrate a beneﬁt of adjuvant chemotherapy
[105]. On the other hand, the LACEmeta-analysis did not show a
negative impact of age on the outcome of adjuvant chemotherapy
[8]. Furthermore, the outcome of elderly patients was not inferior
in the chemoradiotherapy trials by the Cancer and Leukemia
Group B and the RTOG [24]. A recent analysis of data from the
SEER database showed that treatment of elderly patients with
stage IIIA (N2) NSCLC is highly variable in North America and
varies not only with speciﬁc patient and tumour characteristics
but also with regional income level [106]. However, the number
of elderly patients in all randomised adjuvant and chemora-
diotherapy trials is still too small to allow for robust conclusions.
Until more evidence is generated, comorbidity issues should pre-
dominate over age alone with respect to decision making.
performance status
Recommendation 8.2 Reduced PS is a signiﬁcant negative prog-
nostic factor with regard to OS results following a treatment
strategy of surgery plus adjuvant therapy. Treatment planning
must be therefore be individualised [III, B].
While data on age are still controversial, increasingly PS is
accepted as a signiﬁcant negative prognostic factor in stage III
disease. This has been demonstrated in the context of patients
treated by surgery plus adjuvant chemotherapy and also in de-
ﬁnitive chemoradiotherapy protocols [8, 26, 100]. When treat-
ment decisions are to be made for patients with PS Eastern
Cooperative Oncology Group 2, an individual risk/beneﬁt ana-
lysis is particularly important. Medical history (e.g. infections)
resulting in reduced PS should be analysed, and every attempt to
treat a reversible condition and, thereafter, potentially improve
the general condition and PS must be considered.
is there a place for targeted agents in the
treatment of stage III NSCLC?
Recommendation 9: There is currently no role for targeted
agents in stage III NSCLC outside clinical trials [I, A].
The large randomised SWOG trial in North America demon-
strated an inferior OS in a patient group receiving an epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (geﬁtinib)
as consolidation therapy compared with placebo after chemora-
diotherapy and consolidation docetaxel [107]. The reasons for this
detrimental effect are still to be explored, looking at potential spe-
ciﬁc toxicities following chemoradiotherapy and/or docetaxel or
underlying tumour-related adaptive biological mechanisms.
Geﬁtinib was also evaluated as adjuvant treatment in the post-op-
erative setting for stage IB–II–IIIA disease patients in a phase III
underpowered trial, with disappointing results [108]. However, this
study did not select the recruited patient population on the basis of
EGFR mutations. Therefore, any interpretation for the subset of
EGFR mutated patients should be considered with caution. A third
randomised trial has recently been presented—the North
American four-arm randomised trial using cetuximab in addition
to concurrent chemoradiotherapy that was also unable to demon-
strate any beneﬁt from the addition of the targeted agent [83].
Outside well-designed and closely monitored clinical trials in
target-based selected populations, there is currently no role for tar-
geted agents in stage III NSCLC.
what is the optimum follow-up after
radical therapy for stage III NSCLC
patients?
after radical therapy
Recommendation 10.1: Thoracic and upper abdominal CT
scan (including adrenals) should be carried out every 6 months
for 2 years, and yearly thereafter [III, C] for 3 years. No
routine PET-CT is recommended. It might be considered only
in the case of abnormalities detected by CT scan [III, C].
Volume 26 | No. 8 | August 2015 doi:10.1093/annonc/mdv187 | 
Annals of Oncology special articles
No evidence from randomised trials is available to deﬁne optimal
follow-up in treated stage III NSCLC patients. PET-CT—although
of considerable value in initial staging for stage III disease patients
—has no routine role for the follow-up of stage III NSCLC patients
after surgical-based multi-modality treatment [109]. A large
French randomised trial has been carried out to investigate follow-
up in surgically (completely) resected patients with stage I–III and
results are awaited [110]. Currently, experts can only extrapolate
recommendations for follow-up strategies, either based on evi-
dence from follow-up policies in large published clinical trials, in-
dividual physician choices or on consented local (Cancer Centre)
policies. In selected cases, ambiguous abnormalities detected on
CT scans may be individually further investigated with PET-CT
follow-up, but ﬁnal cytological or histological conﬁrmation (e.g.
bronchoscopy, EBUS/EUS) is usually recommended to conﬁrm a
suspicion of relapse.
brain imaging methods
Recommendation 10.2: Patients with stage III disease following
multi-modality treatment have a high risk of brain relapse.
Selected patients with a high risk of brain relapse may be followed
up with brain imaging methods aiming at early detection and
treatment of single-site relapses with curative intent [V, C].
Long-term survival patterns in stage III NSCLC trials have pointed
to the very high cumulative risk of developing brain metastases
after multi-modality treatment [42, 43]. Adenocarcinoma patients,
in particular, may represent a speciﬁc subgroup with an increased
risk proﬁle. Availability of modern radiation techniques for oligo-
metastatic brain lesions in recent years (e.g. stereotactic brain radio-
therapy) may argue in favour of an individualised follow-up using
brain MRI to detect these oligometastatic brain failures, which are
now amenable to local treatment.
smoking cessation
Recommendation 10.3: Patients treated for stage III disease
should be strongly encouraged to quit smoking and/or partici-
pate in smoking cessation programmes [I, A].
Long-term survival analysis, relapse patterns and competing risk
analysis of stage III NSCLC patients including the risk of develop-
ing second lung cancers and smoking-related events (comorbidity
events) are strong arguments to implement smoking cessation pro-
grammes as part of any curatively intended management of early
and locally advanced NSCLC patients including stage III disease
[66, 111, 112].
note
Levels of evidence and grades of recommendation have been
applied using the system shown in Table 1. Statements without
grading were considered justiﬁed standard clinical practice by
the experts and the ESMO faculty.
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